Novavax Inc (NASDAQ:NVAX) is set to start late-stage trials for its COVID-19 vaccine candidate in the UK.
The US firm will enrol up to 10,000 participants aged 18-84 over the next six weeks, with half receiving the formulation and half receiving a placebo.
At least a quarter will be aged 65 and above while there will be a focus on groups most affected by the pandemic such as ethnic minorities.
Up to 400 volunteers will receive both Novavax’s candidate and a seasonal flu vaccine to see if the combination works.
Data for from the Phase II of clinical trials are expected in the fourth quarter of 2020.
The UK struck a deal with Novavax last month to provide support and infrastructure as well as securing 60mln doses if the vaccine is approved.
On Thursday, Westminster announced a new round of funding to the NHS and public services the support needed to respond to coronavirus, with £24.3bn pledged since the Summer Economic Update in July.